- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | AIM - Schedule One - Roquefort Therapeutics PLC | - | RNS | ||
| Mo | Roquefort Theraptcs. - Proposed Acquisition and Fundraise of £8.5 million | - | RNS | ||
| Mi | Roquefort Theraptcs. - Transaction Update & Notice of Intention to Delist | 1 | RNS | ||
| 15.01. | Roquefort Theraptcs. - Research Note Published | 2 | RNS | ||
| 12.12.25 | Roquefort Theraptcs. - Clinical Trial & License Agreement Update | 3 | RNS | ||
| 11.12.25 | XFRA NEW INSTRUMENTS AVAILABLE ON 11.12.2025 | 558 | Xetra Newsboard | The following instruments on XETRA do have their first trading 11.12.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 11.12.2025
Aktien
1 AU0000410128 Ariana Resources PLC
2... ► Artikel lesen | |
| ROQUEFORT THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 09.12.25 | Roquefort Theraptcs. - Conversion of CLNs | - | RNS | ||
| 01.12.25 | Roquefort Therapeutics: Aktie handelt ab heute ex-Anspruch auf unkotierte Aktien | 3 | Investing.com Deutsch | ||
| 01.12.25 | Roquefort Therapeutics shares marked ex-entitlement for unlisted shares | 1 | Investing.com | ||
| 01.12.25 | Roquefort Theraptcs. - Ex-Entitlement Date - Unlisted RNV Shares | - | RNS | ||
| 01.12.25 | Roquefort Theraptcs. - Determination of Record Date and Entitlement | - | RNS | ||
| 24.11.25 | Director dealings: Roquefort Therapeutics director raises stake | 1 | Sharecast | ||
| 24.11.25 | Roquefort Theraptcs. - Director/PDMR Shareholding | - | RNS | ||
| 18.11.25 | Roquefort Theraptcs. - Executed License Agreement & Transaction Update | - | RNS | ||
| 03.11.25 | Roquefort Theraptcs. - MK Cell Out-License & Lyramid SPA Update | - | RNS | ||
| 16.10.25 | Roquefort Therapeutics beschafft 300.000 £ für Akquisition von Krebsmedikament | 2 | Investing.com Deutsch | ||
| 16.10.25 | Roquefort Therapeutics raises £300,000 to fund cancer drug acquisition | 2 | Investing.com | ||
| 16.10.25 | Roquefort Theraptcs. - Fundraise & Transaction Update | - | RNS | ||
| 30.09.25 | EARNINGS: Billington profit dives; Emmerson and Roquefort Therapeutics narrow loss | 2 | Alliance News | ||
| 30.09.25 | Roquefort Theraptcs. - Interim Results to 30 June 2025 | - | RNS |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VIR BIOTECHNOLOGY | 9,340 | 0,00 % | Vir Biotechnology +70%: Deal-Überraschung mit Ansage | Die Aktie von Vir Biotechnology ist vorbörslich um rund 70 Prozent nach oben geschossen. Auslöser der Kursexplosion ist vor allem ein milliardenschwerer Kooperationsdeal mit dem japanischen Pharmakonzern... ► Artikel lesen | |
| ARCELLX | 114,05 | +0,22 % | Weekly Buzz: MGNX's LINNET Trial On Hold; Eton Pharmaceuticals, ALUR Get FDA Nod; GILD Snaps Up ACLX | FOSTER CITY (dpa-AFX) - This week, the biotech space witnessed significant milestones, including FDA approvals, oncology drug acquisitions, and collaborations. Positive clinical trial results... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 90,10 | 0,00 % | Morgan Stanley cuts Kymera Therapeutics stock price target on pipeline progress | ||
| BEAM THERAPEUTICS | 28,690 | +0,74 % | Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street | $100 Million Funded at Close with up to an Additional $400 Million Available Under Facility with Seven-Year Term Financing Bolsters Balance Sheet with Long-term, Non-dilutive Capital to Support Anticipated... ► Artikel lesen | |
| VERA THERAPEUTICS | 40,420 | -0,98 % | Vera Therapeutics, Inc. - 10-K, Annual Report | ||
| ARCUTIS BIOTHERAPEUTICS | 24,760 | -8,25 % | Arcutis Biotherapeutics, Inc.: Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Q4 2025 net product revenue for ZORYVE (roflumilast) was $127.5 million, an 84% increase compared to Q4 2024, and a 29% increase compared to Q3 2025Full year 2025 net product revenue for ZORYVE was... ► Artikel lesen | |
| ERASCA | 14,530 | +6,45 % | Erasca, Inc.: Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001 | The issued patent provides intellectual property protection for ERAS-4001 and related compositions until at least 2043 Expands Erasca's diversified IP portfolio for RAS-driven cancers Initial Phase... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,630 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological insight to meaningful patient outcomes; multiple clinical... ► Artikel lesen | |
| ADMA BIOLOGICS | 16,580 | 0,00 % | ADMA Biologics Announces $200 Mln Capital Return Plan | ||
| TREVI THERAPEUTICS | 12,570 | +5,54 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer | Experienced biotech CFO to lead financial strategy and contribute to the Company's next stage of growth
NEW HAVEN, Conn., Dec. 4, 2025 /PRNewswire/ -- Trevi Therapeutics... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 70,92 | +1,26 % | RBC Capital lowers Apogee Therapeutics stock price target on dosing outlook | ||
| PRAXIS PRECISION MEDICINES | 330,19 | -1,95 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results | Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) have been submitted to the U.S.... ► Artikel lesen | |
| TYRA BIOSCIENCES | 32,520 | -2,63 % | Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights | - Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications -
- Interim Ph2... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 17,680 | 0,00 % | Goldman Questions MoonLake Immunotherapeutics' (MLTX) Sonelokimab Approval Odds Despite Pipeline Update | ||
| KINIKSA PHARMACEUTICALS | 46,040 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution | - ARCALYST- (rilonacept) Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively -- ARCALYST 2026 net product revenue expected to be $900 - $920 million... ► Artikel lesen |
Das Unternehmen ROQUEFORT THERAPEUTICS PLC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,008 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ROQUEFORT THERAPEUTICS PLC finden Sie auf Wallstreet Online.